Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions - Wikidata - awgldk - TriplyDB

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

http://www.wikidata.org/entity/Q26774355

about

Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice.The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters.

P2860

Q38941996-9E12CB33-1E63-47B3-A284-853A97F890AF Q41258130-7FF05FA3-8D1F-4E13-84B3-D5E84E1F794B Q41279707-669ED275-E30E-4ABB-B150-645B4909165D Q49302678-D64DE3B9-FBB6-4D4E-9FFD-8861CDA5C8EE Q50041830-13EEFFAC-2D55-4DDD-B09F-AAC4BA697D2B

P2860

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

http://www.wikidata.org/entity/Q26774355

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@ast

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@en

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@nl

type

label

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@ast

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@en

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@nl

prefLabel

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@ast

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@en

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@nl

P1433

Q26774355-BE706644-1E63-44B5-A972-8F241F76CC77

P1476

Q26774355-BB711561-7297-4BDD-A48B-7CA1B8146EFD

P2093

Q26774355-297D7A40-5FC5-4A2B-B581-13CBF046AB48

Q26774355-50CFE496-531C-42B7-BCA2-88E943760AB0

Q26774355-F5C9463B-96F0-4010-9B7D-3EDF7C09BCD8

P275

Q26774355-46BC282B-DF42-495B-A681-EFF6C86BBFAE

P2860

Q26774355-01D71860-3C55-4613-9EA6-0E19BEA95F63

Q26774355-034CB4F2-3C1F-4E48-9B80-CAD28ED8C1AC

Q26774355-057B1BD5-0E16-4190-80CC-18BFA8103474

Q26774355-05F6258B-7D6C-486D-AF9B-7EA9139C7725

Q26774355-0BD8E488-B72C-45C0-B4B0-BF2ACAAE0CFE

Q26774355-0DC545F6-EE4D-4F1F-A4D5-D4E4D43D6581

Q26774355-0E078B43-815F-4875-B49E-1BC614D5B8A3

Q26774355-0F43F0B4-AA60-4B08-A942-3ABBF45281B1

Q26774355-11CC4225-9DB4-4727-A344-849BC5AF1451

Q26774355-13A33151-E9E1-4E93-9F66-C5FF891277F9

P304

Q26774355-0976AB4B-00EA-40AE-AEBC-28AB095BFA07

P31

Q26774355-12501766-14AA-4D22-AB90-7C09132D6EC0

Q26774355-9357CA4A-B0E3-45FC-84CE-C9299F562471

P356

Q26774355-12BACCBB-3D03-445B-A00A-8931AAEAB614

P407

Q26774355-BDAFD829-457A-4FFE-A7DD-2083450D1C96

P433

Q26774355-4E778DA0-B577-401D-A7DC-EE72E2612412

P478

Q26774355-02F856D6-4C02-4A67-BC10-5246BB2C0811

P577

Q26774355-B3C8252A-28D6-405F-9A5F-BBEB759E9D4F

P698

Q26774355-993A02AA-5A0D-41B1-98FF-B5E7822DAFA4

P921

Q26774355-1E6BD0A7-E7A5-424F-90A7-303DF751AAFA

P932

Q26774355-A97C9191-BA39-4EF6-9E8B-E6D279DD7837

P356

ONCOTARGET.6999

P1433

P1476

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

@en

P2093

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Wenjie Liang

http://www.w3.org/2001/XMLSchema#string

Yicheng Ni

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand

Current role of multiparametric magnetic resonance imaging for prostate cancer

Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy

Diffusion weighted magnetic resonance imaging and its recent trend-a survey

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth

Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI

Angiogenesis in cancer, vascular, rheumatoid and other disease

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

P304

15444-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.6999

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26812886

http://www.w3.org/2001/XMLSchema#string

P921

physiological phenomena

P932

4941252

http://www.w3.org/2001/XMLSchema#string